| Range | 17-85 years | 17-85 years |
| Median | 55 years | 55 years |
| Sex | Sex | Sex |
| Female | 39 | 52.7% |
| Male | 35 | 47.3% |
| Insect | Insect | Insect |
| Bee | 16 | 21.6% |
| Wasp | 58 | 78.4% |
| Treatment | Treatment | Treatment |
| Beta blockers | 3 | 4.1% |
| ACE- inhibitors | 0 | 0% |
| Grade of SR | Grade of SR | Grade of SR |
| I | 0 | 0% |
| II | 20 | 27% |
| III | 46 | 62.1% |
| IV | 8 | 10.8% |
| Reactions during up-dosing (n=74) | Reactions during up-dosing (n=74) | Reactions during up-dosing (n=74) |
| No side effects | 67 | 90.5% |
| Large Local reactions | 4 | 5.4% |
| Subjective systemic symptoms | 3 | 4.1% |
| Objective systemic symptoms | 0 | 0% |
| Total incidence of adverse reactions | 7 | 9.5% |
| Reactions during maintenance (n=74) | Reactions during maintenance (n=74) | Reactions during maintenance (n=74) |
| No side effects | 67 | 90.5% |
| Large Local reactions | 3 | 4.1% |
| Subjective systemic symptoms | 3 | 4.1% |
| Objective systemic symptoms | 1 | 1.4% |
| Total incidence of adverse reactions | 7 | 9.5% |
| Field stings | Field stings | Field stings |
| During up-dosing | During up-dosing | During up-dosing |
| Localised reaction | 5 | 6.8% |
| Systemic reaction | 0 | 0% |
| During maintenance | During maintenance | During maintenance |
| Localised reaction | 15 | 20.3% |
| Systemic reaction | 0 | 0% |